Results 41 to 50 of about 21,216 (279)

Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy. [PDF]

, 2017
Gene therapy by engineering patient's own blood cells to confer HIV resistance can potentially lead to a functional cure for AIDS. Toward this goal, we have previously developed an anti-HIV lentivirus vector that deploys a combination of shRNA, ribozyme ...
Castanotto, Daniela, Li, Haitang, Pang, Ka Ming, Rossi, John J, Scherer, Lisa   +4 more
core   +1 more source

Differential effects of integrase strand transfer inhibitors, elvitegravir and raltegravir, on oligodendrocyte maturation: A role for the integrated stress response

Glia, 2020
Regardless of adherence to combined antiretroviral therapy, white matter and myelin pathologies persist in patients with HIV‐associated neurocognitive disorders, a spectrum of cognitive, motor, and behavioral impairments.
Lindsay M. Roth, B. Zidane, L. Festa, Raj Putatunda, Micah A. Romer, H. Monnerie, K. Jordan-Sciutto, J. Grinspan   +7 more
semanticscholar   +1 more source

Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

CPT: Pharmacometrics & Systems Pharmacology, 2019
Raltegravir readily crosses the placenta to the fetus with maternal use during pregnancy. After birth, neonatal raltegravir elimination is highly variable and often extremely prolonged, with some neonates demonstrating rising profiles after birth despite
Jos Lommerse, Diana Clarke, Thomas Kerbusch, Henri Merdjan, Han Witjes, Hedy Teppler, Mark Mirochnick, Edward P. Acosta, Larissa Wenning, Sharon Nachman, Anne Chain   +10 more
doaj   +1 more source

Selective and rapid determination of raltegravir in human plasma by liquid chromatography–tandem mass spectrometry in the negative ionization mode

Journal of Pharmaceutical Analysis, 2015
A selective and rapid high-performance liquid chromatography–tandem mass spectrometry method was developed and validated for the quantification of raltegravir using raltegravir-d3 as an internal standard (IS).
Ajay Gupta, Swati Guttikar, Priyanka A. Shah, Gajendra Solanki, Pranav S. Shrivastav, Mallika Sanyal   +5 more
doaj   +1 more source

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens

Antimicrobial Resistance and Infection Control, 2020
Background Sub-Saharan African countries are transitioning to dolutegravir-based regimens, even for patients with extensive previous drug exposure, including first-generation integrase strand-transfer inhibitors (INSTI) such as raltegravir. Such exposure
J. Fokam, D. Takou, E. Semengue, G. Této, G. Beloumou, B. Dambaya, M. Santoro, Leonella Mossiang, S. Billong, F. Cham, S. Sosso, E. Temgoua, A. Nanfack, S. Moudourou, N. Kamgaing, R. Kamgaing, Joelle Nounouce Ngako Pamen, Mireille Mpoudi Ngole Etame, A. Bissek, Jean-Bosco N. Elat, E. E. Moussi, V. Colizzi, C. Perno, A. Ndjolo   +23 more
semanticscholar   +1 more source

Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. [PDF]

, 2020
IntroductionWeight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons with HIV (PWH) to cardio-metabolic disease.
Altoff, Keri N, Bourgi, Kassem, Crane, Heidi, Gange, Stephen J, Gill, John, Horberg, Michael A, Jenkins, Cathy A, Kirk, Gregory, Koethe, John R, Lake, Jordan, Li, Jun, Lima, Viviane D, Margolick, Joseph, Mathews, William C, Moore, Richard D, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Palella, Frank, Rabkin, Charles S, Rebeiro, Peter F, Silverberg, Michael, Sterling, Timothy R, Thorne, Jennifer, Willig, Amanda, Wong, Cherise   +23 more
core   +1 more source

Longitudinal sequencing of HIV-1 infected patients with low-level viremia for years while on ART shows no indications for genetic evolution of the virus [PDF]

, 2017
HIV-infected patients on antiretroviral therapy (ART) may present low-level viremia (LLV) above the detection level of current viral load assays.
Dauwe, Kenny, Demecheleer, Els, Dinakis, Sylvie, Hebberecht, Laura, Mortier, Virginie, Vancoillie, Leen, Vaneechoutte, Dries, Verhofstede, Chris   +7 more
core   +1 more source

How developing world concerns need to be part of drug development plans: A case study of four emerging antiretrovirals [PDF]

, 2008
Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries.
Alexandra Calmy, Cahn, Cahn, Chokshi, Cleary, Cohen, Dayam, Esté, Ford, Ford, Jens van Roey, Khoo, Marzolini, Moran, Nathan, Nathan Ford, Pinheiro, Pozniak, Saag, Tido von Schoen-Angerer, Woodfall, World Health Organization, Yeni   +22 more
core   +3 more sources

A case of acanthosis nigricans in a HIV-infected patient [PDF]

, 2020
Background: To date, very little information is available concerning the relationship between acanthosis nigricans (AN) and infection with human immunodeficiency virus type 1 (HIV-1).
De Vincentiis, Ludovica, Di Paolo, Marcello, Iacovelli, Alessandra, Mezzaroma, Ivano, Palange, Paolo, Soda, Giuseppe   +5 more
core   +1 more source

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort [PDF]

, 2019
Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected ...
Abeli C., Acinapura R., alungo A., Andreoni M., Angarano G., Antinori A., aracino A., atini A., azzarin A., Bagella P., Bai F., Baldelli F., Baldin G., Balotta C., Bandera A., Barocci V., Bassetti M., Blanc P., Bobbio N., Bonfanti P., Bonora S., Borderi M., Borgia G., Cacopardo B., Calcagno A., Capetti A., Capobianchi M. R., Capozzi M., Caramello P., Carletti F., Carrara S., Cascio A., Cassola G., Castagna A., Castelli F., Castelnuovo F., Cattelan A. M., Cauda R., Ceccherini-Silberstein F., Ceccherini-Silberstein F., Cecchetto M., Celesia B., Chiodera A., Cicalini S., Cingolani A., Cinque P., Colomba C., Costantini A., Cozzi-Lepri A., Cozzi-Lepri A., Cristaudo A., d'Arminio Monforte A., De Luca A., Di Biagio A., Di Caro A., Di Giuli C., Di Martino F., Di Perri G., Esposito V., Fabrizio C., Falasca K., Fanti I., Fontana Del Vecchio R., Francisci D., Galli L., Galli M., Gentile I., Giacometti I. A., Gianotti N., Girardi E., Gori A., Graziano S., Guaraldi G., i V., Iaiani G., Iardino R., Ippolito G., Lapadula G., lessandrini A., Lichtner M., Lo Caputo S., Lorenzini P., Lorenzotti S., Macchia M., Maddaloni L., Madeddu G., Maggiolo F., Maggiolo F., Magnani G., Manfrin V., Marchetti G., Marinello S., Mastrorosa I., Mazzarello G., Menzaghi B., Migliorino C., Milini P., Minardi C., Moioli M. C., Molteni C., Mondi A., Monno L., Mussini C., Nozza S., Nunnari G., ondero A., Orofino G. C., Pan A., Parruti G., Pellicano G., Pellizzer G., Perno C. F., Petrone F., Piolini R., Plazzi M. M., Pozzetto I., Prota G., Puoti M., Puzzolante C., Quartu S., Quiros Roldan E., Rezza G., Ridolfo A. L., Rivano Capparucia M., Rizzardini G., Rodano' A., Rossetti B., Rossotti R., Rusconi S., Rusconi S., Salpietro S., Sangiovanni V., Santoro M. M., Sarmati L., Savinelli S., Schiaroli E., Sciandra M., Segala D., Sighinolfi L., Sozio F., Starnini G., Suardi C., Tavelli A., Tavelli A., Tincati C., Truffa S., Ursitti M. A., Vecchiet J., Vergori A., Verucchi G., Viale P., Vichi F., Viscoli C., Viviani F., von Schloesser F., Vullo V.   +155 more
core   +4 more sources